Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection

References

• Polaris Observatory C. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383–403.
   PubMed Web of Science ®Google Scholar
• Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016 Sep 10;388(10049):1081–1088.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–398.
   PubMed Web of Science ®Google Scholar
• Garcia PD, Ou JH, Rutter WJ, et al. Targeting of the hepatitis B virus precore protein to the endoplasmic reticulum membrane: after signal peptide cleavage translocation can be aborted and the product released into the cytoplasm. J Cell Biol. 1988 Apr;106(4):1093–1104.
   Web of Science ®Google Scholar
• Standring DN, Ou JH, Masiarz FR, et al. A signal peptide encoded within the precore region of hepatitis B virus directs the secretion of a heterogeneous population of e antigens in Xenopus oocytes. Proc Natl Acad Sci USA. 1988 Nov;85(22):8405–8409.
   Web of Science ®Google Scholar
• Messageot F, Salhi S, Eon P, et al. Proteolytic processing of the hepatitis B virus e antigen precursor. cleavage at two furin consensus sequences. J Biol Chem. 2003 Jan 10;278(2):891–895.
   PubMed Web of Science ®Google Scholar
• Ito K, Kim KH, Lok AS, et al. Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J Virol. 2009 Apr;83(8):3507–3517.
   Web of Science ®Google Scholar
• Eren E, Watts NR, Dearborn AD, et al. Structures of hepatitis B virus core- and e-antigen immune complexes suggest multi-point inhibition. Structure. 2018 Oct 2;26(10):1314–1326. e4.
   Web of Science ®Google Scholar
• Tsai KN, Kuo CF, Ou JJ. Mechanisms of hepatitis B virus Persistence. Trends Microbiol. 2018 Jan;26(1):33–42.
   PubMed Web of Science ®Google Scholar
• Milich DR, Chen MK, Hughes JL, et al. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol. 1998 Feb 15;160(4):2013–2021.
   PubMed Web of Science ®Google Scholar
• Tian Y, Kuo CF, Akbari O, Ou JH. Maternal-derived hepatitis B virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission. Immunity. 2016 May 17;44(5):1204-1214.
   PubMed Web of Science ®Google Scholar
• Lang T, Lo C, Skinner N, et al. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol. 2011 Oct;55(4):762–769.
   PubMed Web of Science ®Google Scholar
• Yu Y, Wan P, Cao Y, et al. Hepatitis B virus e antigen activates the suppressor of cytokine signaling 2 to repress interferon action. Sci Rep. 2017 May 11;7(1):1729.
   Google Scholar
• Cai D, Mills C, Yu W, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother. 2012 Aug;56(8):4277–4288.
   PubMed Web of Science ®Google Scholar
• Bai L, Zhang X, Kozlowski M, et al. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients. J Virol. 2018 Dec 15;92(24).
   Web of Science ®Google Scholar
• Li A, Yuan Q, Huang Z, et al. Novel double-antigen sandwich immunoassay for human hepatitis B core antibody. Clin Vaccine Immunol. 2010 Mar;17(3):464–469.
   PubMedGoogle Scholar
• Ladner SK, Otto MJ, Barker CS, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother. 1997 Aug;41(8):1715–1720.
   PubMed Web of Science ®Google Scholar
• Zhou T, Guo H, Guo JT, et al. Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res. 2006 Nov;72(2):116–124.
   Web of Science ®Google Scholar
• Natrajan A, Wen D. A comparison of chemiluminescent acridinium dimethylphenyl ester labels with different conjugation sites. Org Biomol Chem. 2015 Mar 7;13(9):2622–2633.
   Web of Science ®Google Scholar
• Huang CH, Yuan Q, Chen PJ, et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol. 2012 Oct;57(4):720–729.
   PubMed Web of Science ®Google Scholar
• Arad U. Modified Hirt procedure for rapid purification of extrachromosomal DNA from mammalian cells. Biotechniques. 1998 May;24(5):760–762.
   Web of Science ®Google Scholar
• Qi Y, Gao Z, Xu G, et al. DNA polymerase kappa is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus. PLoS Pathog. 2016 Oct;12(10):e1005893.
   PubMed Web of Science ®Google Scholar
• Yu H, Yuan Q, Ge SX, et al. Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype “I”. PLoS One. 2010 Feb 19;5(2):e9297.
   Web of Science ®Google Scholar
• Li K, Zoulim F, Pichoud C, et al. Critical role of the 36-nucleotide insertion in hepatitis B virus genotype G in core protein expression, genome replication, and virion secretion. J Virol. 2007 Sep;81(17):9202–9215.
   Web of Science ®Google Scholar
• Ou JH, Laub O, Rutter WJ. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc Natl Acad Sci USA. 1986 Mar;83(6):1578–1582.
   PubMed Web of Science ®Google Scholar
• Roossinck MJ, Jameel S, Loukin SH, et al. Expression of hepatitis B viral core region in mammalian cells. Mol Cell Biol. 1986 May;6(5):1393–1400.
   PubMed Web of Science ®Google Scholar
• McLachlan A, Milich DR, Raney AK, et al. Expression of hepatitis B virus surface and core antigens: influences of pre-S and precore sequences. J Virol. 1987 Mar;61(3):683–692.
   Web of Science ®Google Scholar
• Wu G, Liu B, Zhang Y, et al. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother. 2013 Nov;57(11):5344–5354.
   PubMed Web of Science ®Google Scholar
• Mueller H, Wildum S, Luangsay S, et al. A novel orally available small molecule that inhibits hepatitis B virus expression. J Hepatol. 2018 Mar;68(3):412–420.
   Web of Science ®Google Scholar
• Guo H, Jiang D, Zhou T, et al. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol. 2007 Nov;81(22):12472–12484.
   PubMed Web of Science ®Google Scholar
• Buckwold VE, Xu Z, Chen M, et al. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol. 1996 Sep;70(9):5845–5851.
   PubMed Web of Science ®Google Scholar
• Moriyama K, Okamoto H, Tsuda F, et al. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections. Virology. 1996 Dec 15;226(2):269–280.
   Web of Science ®Google Scholar
• Milich DR. Is the function of the HBeAg really unknown? Hum Vaccin Immunother. 2019;15(9):2187–2191.
   PubMed Web of Science ®Google Scholar
• Li H, She Q, Liu Y, et al. Clinical implication and viral mutation in basal core promoter/pre-core of hepatitis B virus C/D recombinant. Hepatol Int. 2018 Sep;12(5):447–455.
   Web of Science ®Google Scholar
• Bayliss J, Yuen L, Rosenberg G, et al. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut. 2017 Nov;66(11):2013–2023.
   Web of Science ®Google Scholar
• Cai D, Wang X, Yan R, et al. Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators. Antiviral Res. 2016 Aug;132:26–37.
   Web of Science ®Google Scholar
• Nassal M, Rieger A. An intramolecular disulfide bridge between Cys-7 and Cys61 determines the structure of the secretory core gene product (e antigen) of hepatitis B virus. J Virol. 1993 Jul;67(7):4307–4315.
   Web of Science ®Google Scholar
• Wasenauer G, Kock J, Schlicht HJ. A cysteine and a hydrophobic sequence in the noncleaved portion of the pre-C leader peptide determine the biophysical properties of the secretory core protein (HBe protein) of human hepatitis B virus. J Virol. 1992 Sep;66(9):5338–5346.
   Web of Science ®Google Scholar
• Ogura N, Watashi K, Noguchi T, et al. Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line. Biochem Biophys Res Commun. 2014 Sep 26;452(3):315–321.
   Web of Science ®Google Scholar